Product Description: Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis[1].
Applications: COVID-19-anti-virus
Formula: C19H22N8O
References: [1]Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019;62(3):1562-1576.
CAS Number: 2120282-75-7
Molecular Weight: 378.43
Compound Purity: 98.89
Research Area: Infection
Solubility: DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)